NewsDialy
Investors who took losses on a Nasdaq-listed stock are being reminded that legal deadlines in an active case are approaching.
A class action, a lawsuit that lets a group of plaintiffs with similar claims pursue them together in one proceeding, has been filed against ADMA Biologics, Inc.
New York firm Pomerantz LLP announced the filing on July 16, 2026.
The suit against ADMA Biologics Pomerantz LLP filed the class action against ADMA Biologics on behalf of investors who say they suffered losses on the stock.
Keep reading